Clinical trial
A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells
NCT03333486 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells
- Lead sponsor
- Roswell Park Cancer Institute
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 7, 2017
- Completion date
- August 28, 2023
- Enrollment
- 31 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
accelerated phase chronic myelogenous leukemia, bcr-abl1 positive, acute leukemia in remission, acute lymphoblastic leukemia, acute myeloid leukemia, acute myeloid leukemia with flt3/itd mutation, acute myeloid leukemia with gene mutations, aplastic anemia, b-cell non-hodgkin lymphoma, cd40 ligand deficiency, chronic granulomatous disease, chronic leukemia in remission, chronic lymphocytic leukemia, chronic myelogenous leukemia, bcr-abl1 positive, chronic myelomonocytic leukemia, chronic phase chronic myelogenous leukemia, bcr-abl1 positive, congenital amegakaryocytic thrombocytopenia, congenital neutropenia, congenital pure red cell aplasia, glanzmann thrombasthenia, immunodeficiency syndrome, myelodysplastic syndrome, myelofibrosis, myeloproliferative neoplasm, paroxysmal nocturnal hemoglobinuria, plasma cell myeloma, polycythemia vera, recurrent non-hodgkin lymphoma, refractory non-hodgkin lymphoma, secondary acute myeloid leukemia, secondary myelodysplastic syndrome, severe aplastic anemia, shwachman-diamond syndrome, sickle cell disease, t-cell non-hodgkin lymphoma, thalassemia, waldenstrom macroglobulinemia, wiskott-aldrich syndrome